Industrial Technology Research Institute

Maggie Lu

Ping-Fu Cheng

Chih-Peng Liu

Yi-Ju Ko

Felice Cheng

Chun-Min Liu

Li-Wen Chang

On Lee

Kuo-Kuei Huang

Ming-Cheng Wei

Tsan-Lin Hu

Jenn-Tsang Hwang

Meng-Nan Lin

Chi-Y Hung

Chia-Yu Fan

Chia-Ching Chen

Ya-Chin Lo

Shuen-Hsiang Chou

Hsiang-Wen Tseng

Shao-Chan Yin

Shih-Ta Chen

Ya-Ling Chiu

Yu-Wen Lo

Wen-Hsuan Chiang

Jheng-Sian Li

May-Hua Chang

Yen-Jen Wang

Wen-Chia Huang

Chien-Lin Pan

A composition for improving the solubility of poorly soluble substances is provided. The composition includes about 40-99.5% by weight of cyclodextrin and/or derivatives thereof; about 0.05-10% by weight of at least one water-soluble polymer; and about 0.05-60% by weight of at least one water-soluble stabilizer.

Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof

A linker-drug represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), C is a conjugator, L is a linker unit, D is a toxin unit, and n is an integer ranging from 1 to 4. The structure of the conjugator is represented by formula (II). In formula (II), X is a leaving group, each of Rand Ris independently a single bond or &#x2014;NH&#x2014;, and Z is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or a combination thereof. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. An antibody-drug conjugate (ADC) employing the above linker-drug is also provided. 

Linker-drug and antibody-drug conjugate (ADC) employing the same

Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C-Calkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C-Calkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis

An antibody-drug conjugate (ADC) of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided. In formula (I), p is an integer ranging from 1 to 26, A is an antibody, and -(L-D) is a linker-drug unit. L is a linker unit having a glycopeptide, and D is a drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. A method for forming an antibody-drug conjugate (ADC) is also provided.A-(L-D)&#x2003;&#x2003;(I)

Antibody-drug conjugate (ADC) and method for forming the same

A hydrogel composition is provided. The hydrogel composition includes polyglutamic acid (PGA) containing maleimide groups, and polyethylene glycol (PEG) containing terminal thiol groups, wherein the hydrogel composition has a pH value ranging from 4.0 to 6.5. A drug delivery system is also provided. The drug delivery system includes the above-mentioned hydrogel composition, and a pharmaceutically active ingredient encapsulated in the hydrogel composition.

Hydrogel compositions and drug delivery systems comprising the same

Growing community of inventors

Zhudong, Taiwan

Maggie Lu